ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 496

Assessment of Anti-Cyclic Citrullinated Protein and Connective Tissue Disease Screening Questionnaire in Healthy Adults from the Oklahoma Immune Cohort

McKayla Muse1, Ly Tran 1, Carla J. Guthridge 2, Nancy Redinger 2 and Judith James 3, 1Oklahoma Medical Research Foundation, Oklahoma City, 2Oklahoma Medical Research Foundation, Oklahoma City, OK, 3Oklahoma Medical Research Foundation, University of Oklahoma Health Sciences Center, Oklahoma City, OK

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: anti-citrullinated protein/peptide antibodies (ACPA), Connective tissue diseases, data analysis and Diagnostic Tests, Rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 10, 2019

Title: RA – Diagnosis, Manifestations, & Outcomes Poster I: Risk Factors, Predictors, & Prognosis

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Anti-CCP antibodies are present in the serum of healthy individuals who are at risk of developing RA and serve as an important tool for diagnosing an individual with RA and providing prognostic information. The Connective Tissue Disease Screening Questionnaire (CSQ) is an assessment designed to help identify individuals who may be at risk for CTDs including RA, SLE, and SS.  We hypothesize that healthy individuals with elevated levels of anti-CCP antibodies will have higher CSQ scores.

Methods: Demographic information (race, gender, and age) and CSQ scores were obtained from the datasets of 954 individuals who consented to be part of the Oklahoma Immune Cohort (OIC).  These individuals were not diagnosed with RA or another autoimmune rheumatic disease.  Anti-CCP3 levels were determined by ELISA.  Individuals were identified as: < 20 EU/mL = negative, 20-39 EU/mL = weakly positive, 40-59 EU/mL= moderately positive, and ≥60EU/mL as strongly positive for anti-CCP3 antibodies.  Associations between CSQ scores and age were determined by Kruskal-Wallis analysis and associations between CSQ scores, race, and gender were determined by Chi-square analysis.  Logistical regression was used to determine the relationship between CSQ scores and anti-CCP3 levels while controlling for age, gender, and race.

Results: CSQ scores and anti-CCP3 levels were both found to be significantly different based upon age or race (Table 1). Healthy Native Americans were more likely to have elevated CSQ scores (OR=1.68) than healthy African Americans (OR=0.86) or heathy European Americans. African-American healthy individuals had the lower rate of anti-CCP3 responses.  Logistic regression analysis, controlling for race, age and gender, showed that there were no significant associations between CSQ and anti-CCP3 levels (Table 2).

Conclusion: In this cohort of healthy adults, anti-CCP3 levels did not associate with variations in the CSQ score. However, anti-CCP3 levels and CSQ scores both varied with age and race, suggesting that these demographic factors may be relevant when screening for risk of developing rheumatic disease.


table1_abstract2019

Table 1: Demographics and Screening Results, Stratified by CSQ Score and CCP3 Interpretation


table2_abstract2019

Table 2: Logistic Regression of Demographics, Stratified by CSQ Score and CCP3 Interpretation


Disclosure: M. Muse, None; L. Tran, None; C. Guthridge, None; N. Redinger, None; J. James, Abbvie, 5, Janssen, 5, Progentec, 2, Progentec Diagnostics, Inc., 2, Xencor, 2, Xencor, Inc., 2.

To cite this abstract in AMA style:

Muse M, Tran L, Guthridge C, Redinger N, James J. Assessment of Anti-Cyclic Citrullinated Protein and Connective Tissue Disease Screening Questionnaire in Healthy Adults from the Oklahoma Immune Cohort [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/assessment-of-anti-cyclic-citrullinated-protein-and-connective-tissue-disease-screening-questionnaire-in-healthy-adults-from-the-oklahoma-immune-cohort/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/assessment-of-anti-cyclic-citrullinated-protein-and-connective-tissue-disease-screening-questionnaire-in-healthy-adults-from-the-oklahoma-immune-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology